17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Oral and contact dissolution of gallstones.

      American journal of surgery
      Administration, Oral, Chenodeoxycholic Acid, therapeutic use, Cholecystography, Cholelithiasis, radiography, therapy, Drug Therapy, Combination, Ethers, Female, Humans, Instillation, Drug, Lithotripsy, Male, Methyl Ethers, Prognosis, Randomized Controlled Trials as Topic, Recurrence, Solvents, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, United States, Ursodeoxycholic Acid

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The appropriate selection of patients for treatment with oral ursodeoxycholic acid (UDCA)--a drug that has virtually no side effects--results in about 50% of patients experiencing safe dissolution of gallstones within 2 years. Eligible patients have small (less than 20 mm in diameter) radiolucent gallstones in a gallbladder visualized by oral cholecystography (OCG); ideal candidates are thin women who have gallstones that are less than 15 mm in diameter, floating when observed by OCG, or of low density on computed tomographic (CT) scanning. Contact dissolution with methyl tert-butyl ether (MTBE) is rapid, effective more often than UDCA, and safe but requires the expertise of an interventional radiologist. Any size and number of cholesterol gallstones that are not CT-dense will be dissolved by MTBE, leaving at most only insoluble debris that is clinically innocuous. Although gallstones recur after dissolution by UDCA or MTBE in 50% of patients within 5 years, recurrent gallstones are usually asymptomatic and/or can probably be dissolved. We conclude that oral or contact dissolution provides an alternative treatment to cholecystectomy for about 30% of patients with symptomatic gallstones.

          Related collections

          Author and article information

          Comments

          Comment on this article